VA marks Avandia off formulary

The bigger they are, the harder they fall? In yet another blow to the embattled diabetes drug Avandia, the Department of Veterans Affairs is severely restricting its use. Until now, the VA accounted for about 8 percent of Avandia sales.

Once upon a time, Avandia delivered $2.2 billion to GlaxoSmithKline's top line in the U.S. alone. Since reports of safety problems surfaced in May, those sales have free-fallen by 60 percent. And more downward pressure may be on its way. Despite an advisory panel's recommendation that it remain on the market, the FDA is still arguing whether to pull the drug.

- read the article from the New York Times

Read more on: GSK | Avandia

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.